Allianz BioInnovation, in collaboration with MOLDOC Biotech and IPHASE, provides ethically sourced, high-quality human hepatocytes and liver cellular fractions to support cutting-edge research in drug metabolism, toxicology, and liver disease modeling.
Offered in both fresh and cryopreserved formats, these cellular preparations are processed under stringent conditions to maintain functional viability and enzymatic activity.
We offer a broad selection of hepatocytes across multiple species and categories—including pooled, single-donor, and specialized subtypes—to meet diverse experimental needs and improve translational relevance.
Key Features
- Ethically Sourced and Fully Characterized:Derived from ethically consented donors, with detailed documentation including age, sex, medical history, and serology.
- Wide Species and Donor Variety: Available from human and multiple preclinical species including single-donor and pooled formats.
- Fresh and Cryopreserved Formats: Supplied as either freshly isolated or cryopreserved cells and subcellular fractions for flexible use.
- High Viability and Metabolic Activity: Optimized isolation and storage protocols ensure high post-thaw viability and preserved Phase I & II enzymatic functions.
- Application-Ready Quality Control: Each batch is QC-tested for viability, protein content, enzyme activity, and sterility, ensuring reliability for ADME, DMPK, and toxicology studies.
More About Product
MOLDOC provides a wide range of high-quality hepatocytes and liver cellular fractions, including animal and human cells in suspension and plateable formats. Human hepatocytes are available with advanced certifications for metabolism, induction, transporter function, and 3D culture. Cellular fractions include microsomes, S9, and cytosol.
IPHASE provides high-quality monkey and human liver tissues, available in 1 cm³ bottles, for advanced research applications. These tissues are ideal for isolating hepatocytes and other liver cellular fractions, supporting studies in drug metabolism, toxicology, and liver disease modeling.
